Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast-Enhanced MRI for Liver Lesions
NCT02156739Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2014
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gadobutrol in Liver lesion, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions at 4 years. Started Oct 2014; status: active, not recruiting.
02
Drugs
gadobutrol
03
Conditions
Liver lesion
Beyond the preview
Go deeper on NCT02156739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156739.